Wegovy (semaglutide 2.4 mg) is one of the most effective FDA-approved weight loss medications available. At roughly $1,350 per month without insurance, coverage decisions from insurers like Cigna are critical for most patients trying to access it.
Cigna coverage for Wegovy is plan-specific. Employer-sponsored commercial plans are most likely to include coverage. Individual marketplace and Medicare Advantage plans typically exclude the medication entirely. In 2025, Cigna introduced a $200-per-month out-of-pocket cap on select employer plans, which expanded access for some patients.
This guide explains exactly how Cigna evaluates Wegovy coverage, what prior authorization requires, and what options exist when coverage is denied. By the end, readers will know exactly where their plan stands and what steps to take next.
Does Cigna Cover Wegovy?
Cigna coverage for Wegovy depends entirely on the specific plan, and most Cigna plans do not include Wegovy for weight loss by default. Coverage is most common in large employer-sponsored commercial plans where the employer has specifically opted into GLP-1 benefits. Individual and Medicare Advantage plans rarely provide coverage.
Cigna administers hundreds of different plan configurations, each with its own drug formulary, exclusion list, and prior authorization criteria. Two patients with identical Cigna insurance cards can have completely different coverage outcomes based on their employer’s benefits decisions.
In 2025, Cigna introduced a $200-per-month out-of-pocket cap for Wegovy and Zepbound on select employer plans through its Evernorth platform. This program did not automatically add coverage for all plans. Employers had to opt in specifically for their employees to benefit.
What Is Wegovy and How Is It Used?
Wegovy is a once-weekly injectable medication containing semaglutide 2.4 mg, FDA-approved in June 2021 for chronic weight management in adults and adolescents aged 12 and older. The FDA granted a second approval in March 2024 for cardiovascular risk reduction in adults with established heart disease who are overweight or obese.
Wegovy works by mimicking GLP-1, a hormone that signals fullness to the brain, slows stomach emptying, and reduces appetite. Patients inject it subcutaneously once per week, starting at 0.25 mg and titrating up over 16 weeks to the 2.4 mg maintenance dose.
Clinical trials show Wegovy produces an average weight loss of 15 percent of body weight over 68 weeks when combined with diet and exercise. Cigna evaluates coverage under two distinct indications: the weight management pathway and the cardiovascular risk reduction pathway, which can produce different coverage outcomes depending on the patient’s diagnosis.
Why Does Cigna Coverage Vary by Plan?
Cigna plan coverage for Wegovy varies because Cigna does not set a single company-wide policy on weight loss drugs. Each employer client negotiates its own benefits package, and the inclusion of GLP-1 medications for obesity is an optional, cost-driven decision that employers make independently.
Large self-funded employer plans carry the most flexibility to add Wegovy coverage because the employer bears the financial risk directly. Fully insured plans purchased by small businesses operate under stricter formularies with fewer customization options. This structural difference explains why two people with Cigna cards can receive entirely different coverage answers for the same medication.
How Does Cigna Decide Whether to Cover Wegovy?
When a Cigna plan does include Wegovy on its formulary, coverage is never automatic. Prior authorization is required in all cases, and the approval process follows Cigna’s national formulary coverage policy for GLP-1 medications, last updated August 27, 2025.
What Are the Prior Authorization Requirements?
Cigna prior authorization for Wegovy requires documented proof of medical necessity, including a qualifying BMI and a record of prior behavioral interventions. The standard criteria require a BMI of 30 kg/m2 or higher, or a BMI of 27 kg/m2 or higher with at least one weight-related comorbidity.
Accepted comorbidities include hypertension, type 2 diabetes, obstructive sleep apnea, and established cardiovascular disease. Patients must document at least three months of behavioral modification, including a reduced-calorie diet and increased physical activity, before Cigna will consider approving the medication.
Additional requirements at initial approval include confirmation that the patient is not currently taking another GLP-1 medication simultaneously. At renewal, Cigna requires documented evidence of at least 5 percent body weight loss from the starting weight. Patients who do not hit the 5 percent threshold face non-renewal of coverage.
Cigna Prior Authorization Criteria for Wegovy:
- BMI 30 kg/m2 or higher, OR BMI 27 kg/m2 with a qualifying comorbidity
- At least 3 months of documented diet and exercise modification
- No concurrent use of another GLP-1 or weight loss medication
- Patient must be 18 years of age or older (or 12+ under the adolescent indication)
- Renewal requires 5 percent or greater weight loss from baseline
What Is Step Therapy and Do You Need It?
Step therapy is a coverage requirement where a patient must try and fail one or more lower-cost treatments before the insurer covers a more expensive option. Some Cigna plans apply step therapy to Wegovy, meaning patients may need to demonstrate that other weight loss interventions failed before approval is granted.
Step therapy requirements vary by plan. Some plans require documented failure of structured behavioral weight loss programs. Others accept the three-month behavioral modification record as sufficient. Patients should ask their prescribing physician to confirm whether their Cigna plan includes step therapy requirements before starting the prior authorization process.
What Are the Benefits of Wegovy for Weight Loss?
Wegovy produces clinically significant weight loss that exceeds what most other FDA-approved medications achieve. In the STEP 1 trial, participants lost an average of 14.9 percent of their body weight over 68 weeks compared to 2.4 percent for placebo. That translates to roughly 15 kilograms (33 pounds) lost for a 100-kilogram (220-pound) person.
Weight loss on Wegovy follows a predictable pattern. Most patients begin losing weight within the first four weeks. The rate of loss peaks around months three through six, then gradually slows as the body adapts. Patients who discontinue the medication typically regain the weight within one to two years.
How Much Weight Can You Lose With Wegovy?
Average weight loss on Wegovy is 15 percent of total body weight over 68 weeks when combined with a reduced-calorie diet and regular exercise. Higher-weight individuals often lose more in absolute terms, while those closer to the 27 kg/m2 BMI threshold may see smaller absolute reductions.
Results vary significantly based on adherence to lifestyle modifications. Patients who pair Wegovy with structured dietary changes and consistent physical activity consistently outperform those who rely on the medication alone. The nutritionists at Eat Proteins emphasize this point: the medication amplifies the effect of behavioral changes, not replaces them.
Does Wegovy Help With More Than Weight?
Wegovy received a second FDA approval in March 2024 for cardiovascular risk reduction in adults with established cardiovascular disease who are obese or overweight. The SELECT trial showed a 20 percent reduction in major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke, among Wegovy users versus placebo.
In August 2025, the FDA approved Wegovy for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults. This is a third FDA-approved indication. Coverage determinations for the MASH indication are still developing across most Cigna plans.
Which Cigna Plan Types Cover Wegovy?
Cigna plan type is the single biggest factor in determining whether Wegovy is covered. Coverage availability ranges from likely to impossible depending on whether the plan is employer-sponsored, ACA marketplace, or Medicare Advantage.
Cigna Plan Types and Wegovy Coverage:
| Plan Type | Coverage Likelihood | Notes |
| Large Employer-Sponsored (Self-Funded) | Possible to Likely | Employer must opt in; PA required |
| Small Employer-Sponsored (Fully Insured) | Unlikely | Stricter formularies; fewer options |
| ACA Marketplace / Individual | Rarely | Weight loss drugs typically excluded |
| Cigna Medicare Advantage | Not Covered | Blocked by federal statute (Medicare Part D) |
| Cigna+Oscar Plans | Varies | Check individual plan formulary |
Do Employer-Sponsored Plans Cover Wegovy?
Large employer-sponsored plans offer the best chance of Wegovy coverage through Cigna. These plans give employers the flexibility to include GLP-1 medications as a covered benefit, and many large corporations and self-funded employers have added Wegovy to their formularies in response to employee demand.
Employees should contact Cigna member services directly and ask two specific questions: first, whether Wegovy (semaglutide 2.4 mg) appears on their plan formulary; second, whether the plan is enrolled in the Evernorth $200-per-month out-of-pocket cap program. Human Resources departments can also provide the summary plan description, which lists covered medications.
Do ACA Marketplace Plans Cover Wegovy?
ACA marketplace plans through Cigna rarely cover Wegovy or other weight loss medications. Federal law does not require individual health insurance plans to cover obesity pharmacotherapy, so most ACA plans exclude these medications entirely to control premium costs.
Patients on ACA marketplace plans who receive Wegovy for cardiovascular risk reduction rather than weight management may have a different coverage pathway. The cardiovascular indication requires a separate diagnosis code, and some plans may cover the medication under the cardiac benefit rather than rejecting it as a weight loss drug.
Does Cigna Medicare Advantage Cover Wegovy?
Cigna Medicare Advantage plans cannot cover Wegovy for weight loss because Medicare Part D is prohibited by federal statute from covering anti-obesity medications. This restriction applies to all Medicare Advantage plans, not just Cigna, and has been in place since Medicare Part D was established.
Proposed federal legislation to allow Medicare coverage of anti-obesity medications has been introduced multiple times but has not passed as of mid-2026. Medicare patients seeking Wegovy must pay out of pocket or explore manufacturer savings programs directly.
What Happens If Cigna Denies Coverage?
A Cigna denial for Wegovy is not a final answer. Patients have the right to appeal any prior authorization denial, and a well-documented appeal reverses many initial rejections. The denial letter must explain the specific reason for rejection, which determines the correct appeal strategy.
How Do You Appeal a Prior Authorization Denial?
Cigna’s appeal process for a PA denial begins with an internal appeal, which must be submitted within the timeframe specified in the denial letter, typically 180 days. The appeal requires a letter of medical necessity from the prescribing physician, documentation of qualifying comorbidities, and records of prior behavioral modification attempts.
Common reasons Cigna denies Wegovy PA requests include incomplete documentation of the three-month behavioral modification period, a BMI below the threshold without a qualifying comorbidity, and concurrent use of another weight loss medication. Each of these denials has a clear remedy. Physicians familiar with Cigna’s criteria can often resolve documentation gaps and resubmit successfully.
If the internal appeal fails, patients can request an external review by an independent medical organization. External reviewers overturn insurer decisions at meaningful rates when the medical documentation is thorough. State insurance commissioners also accept complaints about unjustified coverage denials.
What Are Your Options If Coverage Is Excluded?
When a Cigna plan explicitly excludes Wegovy, an appeal of the exclusion itself rarely succeeds because the exclusion is a plan design decision rather than a medical necessity determination. Patients in this situation have several practical alternatives.
Novo Nordisk offers the Wegovy Savings Offer for commercially insured patients whose plans cover the medication. For patients without coverage, the manufacturer’s cash-pay program through its direct website offers the medication starting at lower price points. Pharmacy discount cards and compounding pharmacies have also served as access pathways, though compounded semaglutide faces increasing regulatory scrutiny from the FDA.
Ready to speed things up? Get a proven weight loss plan built around the same principles that make GLP-1 medications effective.
Options When Cigna Excludes Wegovy:
- Novo Nordisk Wegovy Savings Offer (for plans that cover but require high copays)
- Manufacturer cash-pay direct program
- Pharmacy discount cards (SingleCare, GoodRx)
- Request HR review the employer benefits package at next open enrollment
- Ask prescriber about alternative covered medications (Zepbound, Saxenda, Contrave)
How Long Does It Take to Get Cigna Coverage Approved?
Cigna prior authorization timelines for Wegovy typically run 14 to 30 days from the date of submission to the final coverage decision. Urgent requests with documented medical justification can receive expedited review in 72 hours or less.
What Is the PA Timeline?
Standard PA processing at Cigna requires the prescribing physician to submit clinical documentation through the Cigna provider portal or by fax. Incomplete submissions are the most common cause of delays. A submission that includes all required documentation, including BMI records, comorbidity diagnoses, and behavioral modification notes, typically processes within two weeks.
Patients approved for Wegovy receive a coverage authorization that covers an initial treatment period, typically six months. Before the authorization expires, the treating physician must submit renewal documentation demonstrating at least 5 percent body weight loss from the baseline recorded at the time of initial approval. Missing the renewal window causes coverage to lapse, requiring a new PA submission from the beginning.
What Can You Expect From Wegovy Results?
Wegovy results follow a predictable timeline that most patients can anticipate based on clinical trial data and real-world outcomes. Early results differ from long-term results, and understanding both sets realistic expectations for the treatment period.
When Do Most People See Results?
Most patients notice appetite reduction within the first two to four weeks of starting Wegovy at the 0.25 mg initiation dose. Measurable weight loss typically begins in weeks four through eight. The maximum rate of weight loss generally occurs between months three and six, after patients reach the 2.4 mg maintenance dose.
At week 16, most patients in clinical trials had lost 6 to 8 percent of their starting body weight. By week 68, average loss reached 14.9 percent. Weight loss slows after month six but continues at a lower rate for most patients who maintain the medication and lifestyle modifications. Patients who stop Wegovy regain an average of two-thirds of lost weight within one year, based on the STEP 4 withdrawal trial data.
Want Your Free Weight Loss Plan From Eat Proteins?
You have the information. Now you need the plan. Knowing how Cigna covers Wegovy is step one. Step two is having a structured approach to nutrition and exercise that makes every week count, whether you’re on medication or not.
Our coaches at Eat Proteins have worked with hundreds of patients navigating GLP-1 medications alongside real dietary changes. The free plan they’ve built isn’t generic advice. It’s a protein-focused, appetite-aligned strategy designed to accelerate results and protect muscle mass during weight loss. Don’t leave your results to chance.